378 related articles for article (PubMed ID: 29022746)
1. Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.
Merton K; Davies MJ; Vijapurkar U; Inman D; Meininger G
Curr Med Res Opin; 2018 Feb; 34(2):313-318. PubMed ID: 29022746
[TBL] [Abstract][Full Text] [Related]
2. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials.
Blonde L; Woo V; Mathieu C; Yee J; Vijapurkar U; Canovatchel W; Meininger G
Curr Med Res Opin; 2015 Nov; 31(11):1993-2000. PubMed ID: 26373629
[TBL] [Abstract][Full Text] [Related]
3. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.
Davies MJ; Merton K; Vijapurkar U; Yee J; Qiu R
Cardiovasc Diabetol; 2017 Mar; 16(1):40. PubMed ID: 28327140
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.
John M; Cerdas S; Violante R; Deerochanawong C; Hassanein M; Slee A; Canovatchel W; Hamilton G
Int J Clin Pract; 2016 Sep; 70(9):775-85. PubMed ID: 27600862
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus.
Gavin JR; Davies MJ; Davies M; Vijapurkar U; Alba M; Meininger G
Curr Med Res Opin; 2015; 31(9):1693-702. PubMed ID: 26121561
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
Schernthaner G; Lavalle-González FJ; Davidson JA; Jodon H; Vijapurkar U; Qiu R; Canovatchel W
Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
[TBL] [Abstract][Full Text] [Related]
9. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
Yale JF; Xie J; Sherman SE; Garceau C
Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
Lavalle-González FJ; Eliaschewitz FG; Cerdas S; Chacon Mdel P; Tong C; Alba M
Curr Med Res Opin; 2016; 32(3):427-39. PubMed ID: 26579834
[TBL] [Abstract][Full Text] [Related]
11. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
[TBL] [Abstract][Full Text] [Related]
12. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
Cefalu WT; Stenlöf K; Leiter LA; Wilding JP; Blonde L; Polidori D; Xie J; Sullivan D; Usiskin K; Canovatchel W; Meininger G
Diabetologia; 2015 Jun; 58(6):1183-7. PubMed ID: 25813214
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Stenlöf K; Cefalu WT; Kim KA; Alba M; Usiskin K; Tong C; Canovatchel W; Meininger G
Diabetes Obes Metab; 2013 Apr; 15(4):372-82. PubMed ID: 23279307
[TBL] [Abstract][Full Text] [Related]
14. Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida.
Tanton D; Duh MS; Lafeuille MH; Lefebvre P; Pilon D; Zhdanava M; Emond B; Inman D; Bailey RA
Curr Med Res Opin; 2018 Jun; 34(6):1099-1115. PubMed ID: 29468896
[TBL] [Abstract][Full Text] [Related]
15. Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA
Johnson JF; Parsa R; Bailey RA
Clin Ther; 2017 Jun; 39(6):1123-1131. PubMed ID: 28495028
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.
Fulcher G; Matthews DR; Perkovic V; de Zeeuw D; Mahaffey KW; Mathieu C; Woo V; Wysham C; Capuano G; Desai M; Shaw W; Vercruysse F; Meininger G; Neal B;
Diabetes Obes Metab; 2016 Jan; 18(1):82-91. PubMed ID: 26450639
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Wilding JP; Charpentier G; Hollander P; González-Gálvez G; Mathieu C; Vercruysse F; Usiskin K; Law G; Black S; Canovatchel W; Meininger G
Int J Clin Pract; 2013 Dec; 67(12):1267-82. PubMed ID: 24118688
[TBL] [Abstract][Full Text] [Related]
20. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients.
Babar M; Hussain M; Ahmad M; Akhtar L
J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
